Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 614-619

  Adjei, Alex A ^a   Mandrekar, Sumithra J ^a   Dy, Grace K ^a   Molina, Julian R ^a   Adjei, Araba A ^a   Gandara, David R ^a   Ziegler, Katie L Allen ^a   Stella, Philip J ^a   Rowland Jr , Kendrith M ^a   Schild, Steven E ^a   Zinner, Ralph G ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; PEMETREXED; REDUCED FOLATE CARRIER; 2 O ALPHA D GLUCOPYRANOSYL O BETA D GALACTOPYRANOSYL HYDROXYLYSINE GLUCOHYDROLASE; 2-O-ALPHA-D-GLUCOPYRANOSYL-O-BETA-D-GALACTOPYRANOSYL-HYDROXYLYSINE GLUCOHYDROLASE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DRUG DERIVATIVE; GLUCOSIDASE; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY; PEPTIDE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; EXON; FATIGUE; FEMALE; GERM LINE; HUMAN; HYPERCALCEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; CANCER STAGING; FOLLOW UP; GENETICS; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDASES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE SYNTHASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77449098773     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.6406     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics 2008. CA Cancer J Clin 58:71-96, 2008
2. Schilsky RL: Antimetabolites, in Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkin, 1992, pp 301-315
3. Schultz RM, Patel VF, Worzalla JF, et al: Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 19:437-443, 1999
4. Grem JL: Fluorinated pyrimidines, in Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice. Philadelphia, PA, JB Lippincott, 1990
5. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997
6. Molina JR, Adjei AA: The role of pemetrexed in lung cancer therapy. Clin Lung Cancer 5:21-27, 2003
7. Gorlick R, Cole P, Banerjee D, et al: Mechanisms of methotrexate resistance in acute leukemia: Decreased transport and polyglutamylation. Adv Exp Med Biol 457:543-550, 1999 (Pubitemid 129735350)
8. Gorlick R, Goker E, Trippett T, et al: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89:1013-1018, 1997 (Pubitemid 27121295)
9. Wong SC, Zhang L, Witt TL, et al: Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 274:10388-10394, 1999 (Pubitemid 29180915)
10. Rhee MS, Wang Y, Nair MG, et al: Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 53:2227-2230, 1993 (Pubitemid 23156804)
11. Liani E, Rothem L, Bunni MA, et al: Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 103:587-599, 2003 (Pubitemid 36091461)
12. Zhao R, Babani S, Gao F, et al: The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 6:3687-3695, 2000
13. Leil TA, Endo C, Adjei AA, et al: Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 67:8772-8782, 2007 (Pubitemid 47437453)
14. Adjei AA, Dy GK, Mandrekar S, et al: Pemetrexed pharmacogenomics: Haplotype analysis of transport and activation/inactivation gene polymorphisms and the therapeutic outcome in NSCLC, an NCCTG N0026 based study. J Thorac Oncol 2:pS445 (suppl 4), 2007
15. Barrett JC, Fry B, Maller J, et al: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265, 2005 (Pubitemid 40202029)
16. Omura K: Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: Mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8:132-138, 2003
17. Côté JF, Kirzin S, Kramar A, et al: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275, 2007 (Pubitemid 46944912)
18. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000 (Pubitemid 30415821)
19. Hanna N, Shepher FA, Fossella F, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)